Breast Cancer Prevention Articles & Analysis
11 news found
Tamoxifen Citrate Tamoxifen Citrate is a medication used to treat breast cancer and prevent its recurrence. It works by blocking the effects of estrogen on breast tissue, which can promote the growth of cancer cells. ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: Phase III clinical trial, Flamingo-01, has officially started Multiple sites have ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: As previously disclosed, clinical trial contracts and budgets have been executed ...
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of ...
This may allow GLSI-100 to protect breast cancer survivors over longer periods of time against recurring metastatic breast cancer. ...
The trial, NCT05232916, is currently registered on clinicaltrials.gov and can be seen here. About Breast Cancer and HER2/neu Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 282,000 new breast cancer patients and 3.8 million ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provides an update on the Phase III clinical trial, FLAMINGO-01. ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the expansion of Dr. ...
With the help of LU DF LAB, VITA female oncology patient association, Semper Anticus we are launching Skrinings.lv in Latvia - a digital platform for breast cancer pre-screening, associated risk calculation, and community proactive involvement in research initiatives. Skrinigs.lv is a web platform, available in 3 languages (Latvian, English, Russian) which ...
A review of the scientific literature on women workers and breast cancer, released by the US Breast Cancer Fund, uncovered more than 20 occupations associated with increased risk of breast cancer compared to the risk for the general population. With the release of this report the ...
A new phase of the Breast Cancer and the Environment Research Program (BCERP), focused on prevention, is being launched at the National Institutes of Health. ...